Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II/III trial
Ivarmacitinib significantly enhances multiple dimensions of PROs in active AS patients, supporting its utility in managing PROs in AS. Switching to ivarmacitinib also provides substantial benefits, this indicates that initiating ivarmacitinib treatment, even after an initial period of placebo leads to meaningful improvements in PROs.
Authors
- Qing Shi (ORCID: https://orcid.org/0000-0003-0690-7669)
- Linchen Liu
- Rong Yang (ORCID: https://orcid.org/0000-0002-6112-3149)
- Wei Hua (ORCID: https://orcid.org/0000-0003-4014-989X)
- Dandan Pang (ORCID: https://orcid.org/0000-0001-7224-4723)
- Xiaoyan Xu
Institutions
- Zhongda Hospital Southeast University (CN)
- People's Hospital of Kaizhou District (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.3389/fphar.2025.1710434
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00